EP4562158A1 — Advanced rna targeting (arnatar) for angiotensinogen
Assigned to Arnatar Therapeutics Inc · Expires 2025-06-04 · 1y expired
What this patent protects
Disclosed herein are Advanced RNA Targeting (ARNATAR) dsRNA compounds targeting angiotensinogen (AGT), Such compounds are useful in methods for reducing expression of A GT and for therapeutically treating RAAS associated diseases, disorders and/or conditions, or symptoms thereof …
USPTO Abstract
Disclosed herein are Advanced RNA Targeting (ARNATAR) dsRNA compounds targeting angiotensinogen (AGT), Such compounds are useful in methods for reducing expression of A GT and for therapeutically treating RAAS associated diseases, disorders and/or conditions, or symptoms thereof in a subject.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.